Affiliation:
1. Department of Medical Microbiology, University Medical Center Nijmegen
2. Nijmegen University Center for Infectious Diseases, Nijmegen, The Netherlands
3. Department of Medical Microbiology and Infectious Diseases, Canisius Wilhemina Hospital
Abstract
ABSTRACT
To develop new approaches for the treatment of invasive infections caused by
Aspergillus fumigatus
, the in vitro interactions between itraconazole (ITZ) and seven different nonantimicrobial membrane-active compounds—amiodarone (AMD), amiloride, lidocaine, lansoprazole (LAN), nifedipine (NIF), verapamil, and fluphenazine—against seven ITZ-susceptible and seven ITZ-resistant (ITZ-R) strains were evaluated by the checkerboard microdilution method based on National Committee for Clinical Laboratory Standards M-38A guidelines. The nature and the intensity of the interactions were assessed by a nonparametric approach (fractional inhibitory concentration [FIC] index model), a fully parametric response surface approach (Greco model) of the Loewe additivity no-interaction theory, and the nonparametric (Prichard model) and semiparametric response surface approaches of the Bliss independence (BI) no-interaction theory. Statistically significant synergy was found for the combination of ITZ and AMD and the combination of LAN and NIF, although with different intensities against ITZ-R strains. The FIC index values ranged from 1 to 0.02 for ITZ-AMD, 0.53 to 0.04 for ITZ-LAN, and 0.28 to 0.06 for ITZ-NIF. By use of the BI-based model, the strongest synergy was found for the combination of ITZ with AMD, followed by the combination of ITZ and NIF. The parametric models could not be fit adequately because most of the drugs alone did not show any effect and, thus, no sigmoid dose-response. In general, the combination of ITZ with calcium pump blockers displayed in vitro synergistic activity, primarily against ITZ-R strains, and warrants further investigation.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference54 articles.
1. Aravagiri, M., S. R. Marder, A. Yuwiler, K. K. Midha, N. S. Kula, and R. J. Baldessarini. 1995. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology13:235-247.
2. Benet, L. Z., O. Svein, and J. B. Schwartz. 1996. Design and optimization of dosage regimens; pharmacokinetics data, p. 1765. In P. Molinoff, R. Ruddon, and A. Goodman Gilman (ed.), Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. McGraw-Hill, New York, N.Y.
3. Biswas, S. K., K. Yokoyama, K. Kamei, K. Nishimura, and M. Miyaji. 2001. Inhibition of hyphal growth of Candida albicans by activated lansoprazole, a novel benzimidazole proton pump inhibitor. Med. Mycol.39:283-285.
4. Lancet 1989 ii
5. Bitonti, A. J., A. Sjoerdsma, P. P. McCann, D. E. Kyle, A. M. Oduola, R. N. Rossan, W. K. Milhous, and D. E. Davidson, Jr. 1988. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science242:1301-1303.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献